Significant Ownership of Thomas A. Satterfield Jr.
- Location
- Birmingham, AL
- Summary
- This page shows a list of all the recent SCHEDULE 13D/G filings made by Thomas A. Satterfield Jr..
Follow Filing Activity
Follow Thomas A. Satterfield Jr. and return when a new Schedule 13D/G filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
CIK context first
Continue from Thomas A. Satterfield Jr.
Significant Ownership of Thomas A. Satterfield Jr.
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| ARKR | Ark Restaurants Corp. | Common Stock, par value $0.01 per share | 17% | $5,675,303 | +$438,134 | 622,292 | +8.4% | Thomas A. Satterfield, Jr. | 05 Aug 2025 |
| CRIS | Curis, Inc. | Common Stock, par value $0.01 per share | 9.9% | $2,176,872 | +$1,607,203 | 3,957,950 | +282% | Thomas A. Satterfield, Jr. | 31 Mar 2026 |
| BCDA | BioCardia, Inc. | Common Stock, par value $0.001 per share | 9.9% | $1,356,010 | +$467,153 | 592,144 | +53% | Thomas A. Satterfield, Jr. | 30 Jun 2025 |
| SCND | Scientific Industries, Inc. | Common Stock, $.05 par value | 9.9% | $1,183,577 | 1,138,055 | Thomas A. Satterfield, Jr. | 31 Dec 2024 | ||
| OSTX | OS Therapies Incorporated | Common Stock, par value $0.001 per share | 9.4% | $5,296,658 | +$3,141,967 | 3,115,681 | +146% | Thomas A. Satterfield, Jr. | 30 Jun 2025 |
| NVNO | enVVeno Medical Corporation | Common Stock, $0.00001 par value per share | 9% | $1,348,650 | 1,822,500 | Thomas A. Satterfield, Jr. | 14 Nov 2025 | ||
| CTSO | CytoSorbents Corporation | Common Stock, par value $0.001 per share | 6.6% | $4,638,686 | 3,998,867 | Thomas A. Satterfield, Jr. | 13 Jan 2025 | ||
| ALCO | Alico, Inc. | Common Stock | 6.4% | $17,711,970 | 486,836 | Thomas A. Satterfield, Jr. | 31 Dec 2025 | ||
| LTRN | Lantern Pharma Inc. | Common Stock, $0.0001 par value per share | 5.1% | $1,727,100 | 570,000 | Thomas A. Satterfield, Jr. | 30 Mar 2026 | ||
| CHRS | Coherus Oncology, Inc. | Common Stock, $0.0001 par value per share | 4.6% | $11,711,700 | +$1,555,621 | 6,930,000 | +15% | Thomas A. Satterfield, Jr. | 31 Mar 2026 |
| INTT | inTest Corporation | Common Stock, par value $0.01 per share | 4.4% | $7,507,500 | -$6,150,608 | 550,000 | -45% | Thomas A. Satterfield, Jr. | 31 Mar 2026 |
| EDSA | Edesa Biotech, Inc. | Common Stock, without par value | 0% | $0 | -$547,900 | 0 | -100% | Thomas A. Satterfield, Jr. | 13 Feb 2025 |
Schedules 13D/G Reported by Thomas A. Satterfield Jr.:
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.